![Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer | Scientific Reports Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-97564-1/MediaObjects/41598_2021_97564_Fig1_HTML.png)
Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer | Scientific Reports
Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer | PLOS ONE
![CA125, YKL-40, HE-4 and Mesothelin: a new serum biomarker combination in discrimination of benign and malign epithelial ovarian tumor CA125, YKL-40, HE-4 and Mesothelin: a new serum biomarker combination in discrimination of benign and malign epithelial ovarian tumor](https://www.degruyter.com/document/doi/10.1515/tjb-2019-0038/asset/graphic/j_tjb-2019-0038_fig_005.jpg)
CA125, YKL-40, HE-4 and Mesothelin: a new serum biomarker combination in discrimination of benign and malign epithelial ovarian tumor
![Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer | Journal of Ovarian Research | Full Text Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer | Journal of Ovarian Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13048-020-00681-0/MediaObjects/13048_2020_681_Fig2_HTML.png)
Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer | Journal of Ovarian Research | Full Text
Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer | PLOS ONE
![Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study | SpringerLink Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12282-020-01058-3/MediaObjects/12282_2020_1058_Fig2_HTML.png)
Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study | SpringerLink
![Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy - Gynecologic Oncology Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy - Gynecologic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/f2225cad-6924-4515-a7dd-0006f51b9cdf/gr1.jpg)
Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy - Gynecologic Oncology
![Serum CA 125 is of clinical value in the staging and follow‐up of patients with non‐hodgkin's lymphoma - Lazzarino - 1998 - Cancer - Wiley Online Library Serum CA 125 is of clinical value in the staging and follow‐up of patients with non‐hodgkin's lymphoma - Lazzarino - 1998 - Cancer - Wiley Online Library](https://acsjournals.onlinelibrary.wiley.com/cms/asset/bb9bb199-b653-47b7-8993-12e910629806/mfig001.jpg)
Serum CA 125 is of clinical value in the staging and follow‐up of patients with non‐hodgkin's lymphoma - Lazzarino - 1998 - Cancer - Wiley Online Library
![PDF] Pediatric population reference value distributions for cancer biomarkers and covariate-stratified reference intervals in the CALIPER cohort. | Semantic Scholar PDF] Pediatric population reference value distributions for cancer biomarkers and covariate-stratified reference intervals in the CALIPER cohort. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/06c3dcc8efc9a1f23e1d101401973faade359a6c/2-Table1-1.png)
PDF] Pediatric population reference value distributions for cancer biomarkers and covariate-stratified reference intervals in the CALIPER cohort. | Semantic Scholar
![JCM | Free Full-Text | CA125 as a Marker of Heart Failure in the Older Women: A Population-Based Analysis | HTML JCM | Free Full-Text | CA125 as a Marker of Heart Failure in the Older Women: A Population-Based Analysis | HTML](https://www.mdpi.com/jcm/jcm-08-00607/article_deploy/html/images/jcm-08-00607-g0A1.png)
JCM | Free Full-Text | CA125 as a Marker of Heart Failure in the Older Women: A Population-Based Analysis | HTML
![Frontiers | Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition | Immunology Frontiers | Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition | Immunology](https://www.frontiersin.org/files/Articles/663379/fimmu-12-663379-HTML-r1/image_m/fimmu-12-663379-g001.jpg)
Frontiers | Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition | Immunology
Identifying the Best Marker Combination in CEA, CA125, CY211, NSE, and SCC for Lung Cancer Screening by Combining ROC Curve and Logistic Regression Analyses: Is It Feasible?
![Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer | Journal of Ovarian Research | Full Text Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer | Journal of Ovarian Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13048-020-00681-0/MediaObjects/13048_2020_681_Fig3_HTML.png)
Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer | Journal of Ovarian Research | Full Text
![Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial - Annals of Oncology Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b36ed5bf-7780-4454-a65f-1708179ea117/gr1_lrg.jpg)